A new study1 published in Hepatology Communications, demonstrates that HBV test platforms are not interchangeable. If your HBV DNA assay amplifies RNA to measure viral loads, it could be overquantifying. This may lead to the mis-classification of treatment responses and unnecessary clinical interventions due to perceived treatment failure.
To learn more about the assessment

Watch the video below to hear from a clinician who had experience with this situation.
 
Watch a video of Anna Maria Geretti, MD, PhD, FRCPath, Roche Expert Scientist, Professor of Virology & Infectious Diseases at the Institute of Infection & Global Health of the University of Liverpool, and Honorary Consultant at the Royal Liverpool University Hospital, where she discusses the consequences of over-quantification of HBV DNA viral loads on the treatment of her patients.
Learn more about HBV Assay
 
Or, Get in touch with us right now
Form Successfully Submitted!
Thank you for your submission!
text
 
 
Complaint reporting

 

Please do not use this form to report complaints or adverse events or to ask any questions regarding medical products. 

To report a complaint or adverse event, please contact Roche Local Safety Units in your country.



1. Maasoumy, B., et al. (2020), Hepatol Commun, 4: 983-997